Colombia
|
Potential drugs for the treatment of the novel coronavirus pneumonia (COVID-19) in China
Autor
Pan, Xiaoqi
Dong, Lan
Yang, Lian
Chen, Dayi
Peng, Cheng
Institución
Resumen
The fight against the novel coronavirus pneumonia (namely COVID-19) that seriously harms human health is a
common task for all mankind. Currently, development of drugs against the novel coronavirus (namely SARSCoV-2) is quite urgent. Chinese medical workers and scientific researchers have found some drugs to play potential therapeutic effects on COVID-19 at the cellular level or in preliminary clinical trials. However, more
fundamental studies and large sample clinical trials need to be done to ensure the efficacy and safety of these
drugs. The adoption of these drugs without further testing must be careful. The relevant articles, news, and
government reports published on the official and Preprint websites, PubMed and China National Knowledge
Infrastructure (CNKI) databases from December 2019 to April 2020 were searched and manually filtered. The
general pharmacological characteristics, indications, adverse reactions, general usage, and especially current
status of the treatment of COVID-19 of those potentially effective drugs, including chemical drugs, traditional
Chinese medicines (TCMs), and biological products in China were summarized in this review to guide reasonable
medication and the development of specific drugs for the treatment of COVID-19.